Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat α-Cells by a Protein Kinase A–Mediated Mechanism

High-resolution capacitance measurements were used to explore the effects of the gut hormones GLP-1(7-36) amide [glucagon-like peptide I(7-36) amide] and GIP (glucose-dependent insulinotropic polypeptide) on Ca2+-dependent exocytosis in glucagon-secreting rat pancreatic ケ-cells. Both peptides produced a greater than threefold potentiation of secretion evoked by voltage-clamp depolarizations, an effect that was associated with an ∼35% increase of the Ca2+ current. The stimulatory actions of GLP-I(7-36) amide and GIP were mimicked by forskolin and antagonized by the protein kinase A (PKA)- inhibitor Rp-8-Br-cAMPS. The islet hormone somatostatin inhibited the stimulatory action of GLP-I(7-36) amide and GIP via a cyclic AMP–independent mechanism, whereas insulin had no effect on exocytosis. These data suggest that the α-cells are equipped with receptors for GLP-I and GIP and that these peptides, in addition to their well-established insulinotropic capacity, also stimulate glucagon secretion. We propose that the reported inhibitory action of GLP-I on glucagon secretion is accounted for by a paracrine mechanism (e.g., mediated by stimulated release of somatostatin that in turn suppresses exocytosis in the α-cell).

[1]  J. Habener,et al.  Insulinotropic Glucagon-Like Peptide I Receptor Expression in Glucagon-Producing α-Cells of the Rat Endocrine Pancreas , 1997, Diabetes.

[2]  P. Rorsman,et al.  Neurotransmitter-Induced Inhibition of Exocytosis in Insulin-Secreting β Cells by Activation of Calcineurin , 1996, Neuron.

[3]  P. Berggren,et al.  Fluorescence-activated cell sorted rat islet cells and studies of the insulin secretory process. , 1996, The Journal of endocrinology.

[4]  R. Heller,et al.  Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide. , 1995, The American journal of physiology.

[5]  B. Thorens.  Glucagon-like peptide-1 and control of insulin secretion. , 1995, Diabete & metabolisme.

[6]  C. Widmann,et al.  Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. , 1995, The Biochemical journal.

[7]  B. Göke,et al.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. , 1995, Endocrine reviews.

[8]  F. Ashcroft,et al.  Exocytosis elicited by action potentials and voltage‐clamp calcium currents in individual mouse pancreatic B‐cells. , 1993, The Journal of physiology.

[9]  F. Ashcroft,et al.  Regulation of glucagon release from pancreatic A-cells. , 1991, Biochemical pharmacology.

[10]  Kim Cooper,et al.  Low access resistance perforated patch recordings using amphotericin B , 1991, Journal of Neuroscience Methods.

[11]  J. Habener,et al.  Functional receptors for the insulinotropic hormone glucagon‐like peptide‐I(7–37) on a somatostatin secreting cell line , 1991, FEBS letters.

[12]  W. Fujimoto,et al.  Effects of Glucagonlike Peptide l-(7–36) on Release of Insulin, Glucagon, and Somatostatin by Rat Pancreatic Islet Cell Monolayer Cultures , 1989, Diabetes.

[13]  M. Namba,et al.  Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide , 1989, Diabetes.

[14]  S. Ohashi,et al.  Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. , 1989, Endocrinology.

[15]  R. Horn,et al.  Muscarinic activation of ionic currents measured by a new whole-cell recording method , 1988, The Journal of general physiology.

[16]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[17]  P. Rorsman,et al.  Calcium and delayed potassium currents in mouse pancreatic beta‐cells under voltage‐clamp conditions. , 1986, The Journal of physiology.

[18]  V. Rogiers,et al.  Pancreatic hormone receptors on islet cells. , 1985, Endocrinology.

[19]  W. Stec,et al.  Inhibitory action of certain cyclophosphate derivatives of cAMP on cAMP-dependent protein kinases. , 1984, European journal of biochemistry.

[20]  E Neher,et al.  Discrete changes of cell membrane capacitance observed under conditions of enhanced secretion in bovine adrenal chromaffin cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Widmann,et al.  Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. , 1996, Molecular endocrinology.

[22]  P. Rorsman,et al.  Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKA-independent mechanisms. , 1996, British journal of pharmacology.

[23]  T. Walseth,et al.  Somatostatin selectively couples to G(o) alpha in HIT-T15 cells. , 1995, Diabetes.

[24]  B. Göke,et al.  Molecular and functional characterization of insulin receptors present on hamster glucagonoma cells. , 1994, Digestion.

[25]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.